首页 > 最新文献

Basic & Clinical Pharmacology & Toxicology最新文献

英文 中文
Epidemiology of New Psychoactive Substances in Relation to Traditional Drugs of Abuse in Clinical Oral Fluid Samples
IF 2.7 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2025-01-13 DOI: 10.1111/bcpt.14117
Magnus A. B. Axelsson, Hanna Lövgren, Robert Kronstrand, Henrik Green, Moa Andresen Bergström

New psychoactive substances (NPS) are health-hazardous through unpredictable toxicity and effects and largely unknown epidemiology, motivating studies of the latter.

Up to 138 NPS were retrospectively identified using liquid chromatography-high resolution mass spectrometry data from all 34 183 oral fluid drug samples collected in one Swedish health care region 2019–2020 representing 9468 psychiatric and addiction care patients. In total, 618 findings representing 58 NPS were detected in 481 samples from 201 patients. Male gender and age ≥25 years correlated positively with NPS use. Ketamine correlated positively with all NPS classes except cannabinoids; additionally, fentanyl, methadone, tapentadol and clonazepam correlated with multiple NPS classes. More numerous traditional drugs of abuse (DoA) correlated positively with sedative/hypnotic NPS, indicating that these are used in broader patient groups than other NPS. Mitragynine correlated negatively with other NPS in general and with several traditional DoA, but positively with the potential opioid abstinence remedies buprenorphine, loperamide and tapentadol aside from ketamine. In conclusion, NPS use is infrequent but occur also at higher ages, certain traditional DoA and particularly ketamine could have clinical value as NPS use signals, and mitragynine exhibited an atypical NPS consumption pattern indicating significant use as an opioid abstinence remedy.

{"title":"Epidemiology of New Psychoactive Substances in Relation to Traditional Drugs of Abuse in Clinical Oral Fluid Samples","authors":"Magnus A. B. Axelsson,&nbsp;Hanna Lövgren,&nbsp;Robert Kronstrand,&nbsp;Henrik Green,&nbsp;Moa Andresen Bergström","doi":"10.1111/bcpt.14117","DOIUrl":"10.1111/bcpt.14117","url":null,"abstract":"<p>New psychoactive substances (NPS) are health-hazardous through unpredictable toxicity and effects and largely unknown epidemiology, motivating studies of the latter.</p><p>Up to 138 NPS were retrospectively identified using liquid chromatography-high resolution mass spectrometry data from all 34 183 oral fluid drug samples collected in one Swedish health care region 2019–2020 representing 9468 psychiatric and addiction care patients. In total, 618 findings representing 58 NPS were detected in 481 samples from 201 patients. Male gender and age ≥25 years correlated positively with NPS use. Ketamine correlated positively with all NPS classes except cannabinoids; additionally, fentanyl, methadone, tapentadol and clonazepam correlated with multiple NPS classes. More numerous traditional drugs of abuse (DoA) correlated positively with sedative/hypnotic NPS, indicating that these are used in broader patient groups than other NPS. Mitragynine correlated negatively with other NPS in general and with several traditional DoA, but positively with the potential opioid abstinence remedies buprenorphine, loperamide and tapentadol aside from ketamine. In conclusion, NPS use is infrequent but occur also at higher ages, certain traditional DoA and particularly ketamine could have clinical value as NPS use signals, and mitragynine exhibited an atypical NPS consumption pattern indicating significant use as an opioid abstinence remedy.</p>","PeriodicalId":8733,"journal":{"name":"Basic & Clinical Pharmacology & Toxicology","volume":"136 2","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11730279/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143055775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction to ‘Decreased Blood Pressure With Acute Administration of Quercetin in L-NAME-Induced Hypertensive Rats’ 更正“l - name诱导高血压大鼠急性给予槲皮素降低血压”。
IF 2.7 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2025-01-13 DOI: 10.1111/bcpt.14130

Mkhize, SA, Nthlane, RA, Xhakaza, SP, et al. Decreased Blood Pressure With Acute Administration of Quercetin in L-NAME-Induced Hypertensive Rats. Basic Clin Pharmacol Toxicol. 2025; 136(1):e14113. https://doi.org/10.1111/bcpt.14113

In the article cited above, Figure 7 was published with an incorrect label on the x-axis. The corrected figure and legend are published below.

We apologize for this error.

{"title":"Correction to ‘Decreased Blood Pressure With Acute Administration of Quercetin in L-NAME-Induced Hypertensive Rats’","authors":"","doi":"10.1111/bcpt.14130","DOIUrl":"10.1111/bcpt.14130","url":null,"abstract":"<p>\u0000 <span>Mkhize, SA</span>, <span>Nthlane, RA</span>, <span>Xhakaza, SP</span>, et al. <span>Decreased Blood Pressure With Acute Administration of Quercetin in L-NAME-Induced Hypertensive Rats</span>. <i>Basic Clin Pharmacol Toxicol</i>. <span>2025</span>; <span>136</span>(<span>1</span>):e14113. https://doi.org/10.1111/bcpt.14113\u0000 </p><p>In the article cited above, Figure 7 was published with an incorrect label on the x-axis. The corrected figure and legend are published below.</p><p>We apologize for this error.</p>","PeriodicalId":8733,"journal":{"name":"Basic & Clinical Pharmacology & Toxicology","volume":"136 2","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bcpt.14130","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142977415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Understanding the Importance of the Small Artery Media–Lumen Ratio: Past and Present 了解小动脉中腔比的重要性:过去和现在。
IF 2.7 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2025-01-13 DOI: 10.1111/bcpt.14127
Christian Aalkjaer

The media–lumen diameter ratio of small arteries is increased in hypertension, diabetes and obesity. It is likely that both shear stress on the endothelial cells, transmural pressure and smooth muscle cell tone are important for the altered vascular structure. However, the precise interaction and importance of these factors are incompletely understood. At the molecular level transglutaminases, metalloproteinases, integrins, NO and several other factors have been suggested to be important, but our understanding of how the many factors together control vascular structure is surprisingly limited. The media–lumen diameter ratio of the small arteries has prognostic value, which is independent of the classical risk factors for cardiovascular disease. Importantly this is also the case in patients treated pharmacologically for high blood pressure. It is therefore relevant to consider small artery structure as a potential target in relation to prevention of cardiovascular disease.

高血压、糖尿病和肥胖症患者小动脉中腔直径比升高。内皮细胞的剪切应力、跨壁压力和平滑肌细胞张力可能是血管结构改变的重要原因。然而,这些因素的确切相互作用和重要性尚未完全了解。在分子水平上,转谷氨酰胺酶、金属蛋白酶、整合素、NO和其他几个因素被认为是重要的,但我们对这些因素如何共同控制血管结构的理解却令人惊讶地有限。小动脉中腔直径比具有独立于心血管疾病经典危险因素的预后价值。重要的是,这也适用于接受药物治疗的高血压患者。因此,考虑小动脉结构作为预防心血管疾病的潜在目标是相关的。
{"title":"Understanding the Importance of the Small Artery Media–Lumen Ratio: Past and Present","authors":"Christian Aalkjaer","doi":"10.1111/bcpt.14127","DOIUrl":"10.1111/bcpt.14127","url":null,"abstract":"<p>The media–lumen diameter ratio of small arteries is increased in hypertension, diabetes and obesity. It is likely that both shear stress on the endothelial cells, transmural pressure and smooth muscle cell tone are important for the altered vascular structure. However, the precise interaction and importance of these factors are incompletely understood. At the molecular level transglutaminases, metalloproteinases, integrins, NO and several other factors have been suggested to be important, but our understanding of how the many factors together control vascular structure is surprisingly limited. The media–lumen diameter ratio of the small arteries has prognostic value, which is independent of the classical risk factors for cardiovascular disease. Importantly this is also the case in patients treated pharmacologically for high blood pressure. It is therefore relevant to consider small artery structure as a potential target in relation to prevention of cardiovascular disease.</p>","PeriodicalId":8733,"journal":{"name":"Basic & Clinical Pharmacology & Toxicology","volume":"136 2","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bcpt.14127","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142977428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patient-Related Factors Associated With the Initiation of Potentially Inappropriate Medication in Home Care: An Observational Study Based on Resident Assessment Instrument Data 与家庭护理中可能不适当用药相关的患者相关因素:一项基于住院医师评估工具数据的观察性研究。
IF 2.7 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2025-01-08 DOI: 10.1111/bcpt.14125
Jasmin Paulamäki, Johanna Jyrkkä, Virva Hyttinen-Huotari, Heini Huhtala, Esa Jämsen

Background

The harmful outcomes of potentially inappropriate medications (PIMs) are highlighted among multimorbid older home care clients using several medicines. The aim of this study was to identify patient-related factors associated with the initiation of PIMs.

Methods

This register-based study used Resident Assessment Instrument-Home Care (RAI-HC) assessments (n = 6176) from year 2014 to 2015. PIMs were identified according to the Beers criteria. Generalised estimating equations were used to identify factors associated with the initiation of PIMs.

Findings

A total of 228 (11.3%) clients initiated PIMs during the follow-up (mean 13 months). Factors associated with higher odds to initiate PIMs were higher education (OR = 1.36, 95% CI 1.02–1.82), cognitive impairment (OR = 1.70, 1.02–2.82), reduced social interaction (OR = 1.50, 1.06–2.13), independent activity outdoors (OR = 1.72, 1.18–2.51), diabetes (OR = 1.47, 1.12–1.94), Parkinson's disease (OR = 3.42, 1.86–6.27) and longer interval between RAI assessments (OR = 1.09 per month, 1.02–1.18).

Conclusions

Incidence of PIMs among home care clients was common. The results help healthcare professionals to focus more attention on clients more susceptible to PIM prescribing. Preventing PIM use is essential, especially among older adults with cognitive impairment, to prevent further decline of health status and admission to long-term care.

背景:在使用多种药物的多病老年家庭护理客户中,潜在不适当药物(PIMs)的有害后果得到了强调。本研究的目的是确定与PIMs启动相关的患者相关因素。方法:本研究采用2014 - 2015年居民评估工具-家庭护理(RAI-HC)评估(n = 6176)。pim是根据Beers标准确定的。使用广义估计方程来确定与pim启动相关的因素。结果:在随访期间(平均13个月),共有228名(11.3%)患者启动了pim。与启动pim的较高几率相关的因素是高等教育(OR = 1.36, 95% CI 1.02-1.82)、认知障碍(OR = 1.70, 1.02-2.82)、社会交往减少(OR = 1.50, 1.06-2.13)、独立户外活动(OR = 1.72, 1.18-2.51)、糖尿病(OR = 1.47, 1.12-1.94)、帕金森病(OR = 3.42, 1.86-6.27)和RAI评估间隔较长(OR = 1.09每月,1.02-1.18)。结论:家庭护理患者中不良情绪的发生率较高。研究结果有助于医疗保健专业人员将更多的注意力集中在更容易受到PIM处方影响的客户身上。预防PIM的使用至关重要,特别是在有认知障碍的老年人中,以防止健康状况进一步下降和接受长期护理。
{"title":"Patient-Related Factors Associated With the Initiation of Potentially Inappropriate Medication in Home Care: An Observational Study Based on Resident Assessment Instrument Data","authors":"Jasmin Paulamäki,&nbsp;Johanna Jyrkkä,&nbsp;Virva Hyttinen-Huotari,&nbsp;Heini Huhtala,&nbsp;Esa Jämsen","doi":"10.1111/bcpt.14125","DOIUrl":"10.1111/bcpt.14125","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The harmful outcomes of potentially inappropriate medications (PIMs) are highlighted among multimorbid older home care clients using several medicines. The aim of this study was to identify patient-related factors associated with the initiation of PIMs.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This register-based study used Resident Assessment Instrument-Home Care (RAI-HC) assessments (<i>n</i> = 6176) from year 2014 to 2015. PIMs were identified according to the Beers criteria. Generalised estimating equations were used to identify factors associated with the initiation of PIMs.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Findings</h3>\u0000 \u0000 <p>A total of 228 (11.3%) clients initiated PIMs during the follow-up (mean 13 months). Factors associated with higher odds to initiate PIMs were higher education (OR = 1.36, 95% CI 1.02–1.82), cognitive impairment (OR = 1.70, 1.02–2.82), reduced social interaction (OR = 1.50, 1.06–2.13), independent activity outdoors (OR = 1.72, 1.18–2.51), diabetes (OR = 1.47, 1.12–1.94), Parkinson's disease (OR = 3.42, 1.86–6.27) and longer interval between RAI assessments (OR = 1.09 per month, 1.02–1.18).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Incidence of PIMs among home care clients was common. The results help healthcare professionals to focus more attention on clients more susceptible to PIM prescribing. Preventing PIM use is essential, especially among older adults with cognitive impairment, to prevent further decline of health status and admission to long-term care.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8733,"journal":{"name":"Basic & Clinical Pharmacology & Toxicology","volume":"136 2","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11712029/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142942956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Initiation of Anticoagulants During the COVID-19 Pandemic in Sweden: An Interrupted Time Series Analysis 瑞典COVID-19大流行期间抗凝血剂的启动:中断时间序列分析。
IF 2.7 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2025-01-05 DOI: 10.1111/bcpt.14119
Per-Jostein Samuelsen, Björn Wettermark, Fredrik Nyberg, Mohammadhossein Hajiebrahimi

The COVID-19 pandemic may have increased anticoagulant initiation due to the thrombogenic nature of the disease or decreased due to the societal impact of the pandemic. We aimed to study the effect of the COVID-19 pandemic on initiation of anticoagulants in Sweden. We conducted a single interrupted time series analysis on the monthly cumulative incidence of nonvitamin K antagonist oral anticoagulants (NOAC), warfarin, or heparins, before and after March 2020, using SCIFI-PEARL dataset. For anticoagulants in total, there were no statistically significant changes or differences in the trends of initiation after the start of the pandemic. There was a slight numerical decrease in initiation after the onset of the pandemic, particularly for NOACs. For individuals aged ≥ 65 years, however, the immediate decrease in initiation was considerable for NOACs. The prepandemic declining trend of warfarin initiation seemed to attenuate, that is, became less negative, after March 2020. We did not find any profound effect of the COVID-19 pandemic on the initiation of anticoagulants in total. However, among individuals aged ≥ 65 years, a notable immediate decrease in initiation of NOACs was observed. Furthermore, the onset of the pandemic may have attenuated the downward temporal trend in initiation of warfarin use.

COVID-19大流行可能由于该疾病的致血栓性而增加了抗凝剂的使用,也可能由于大流行的社会影响而减少了抗凝剂的使用。我们的目的是研究COVID-19大流行对瑞典开始使用抗凝血剂的影响。我们使用SCIFI-PEARL数据集对2020年3月前后非维生素K拮抗剂口服抗凝剂(NOAC)、华法林或肝素的月累积发病率进行了单中断时间序列分析。总的来说,在大流行开始后,抗凝剂的使用趋势没有统计学上的显著变化或差异。在大流行开始后,特别是对国家和地区国家而言,启动数量略有减少。然而,对于年龄≥65岁的个体,NOACs的起始率立即下降相当大。在2020年3月之后,华法林大流行前的下降趋势似乎减弱,即变得不那么消极。总的来说,我们没有发现COVID-19大流行对抗凝剂的使用有任何深刻的影响。然而,在年龄≥65岁的个体中,观察到NOACs的起始率显着立即下降。此外,大流行的爆发可能减弱了华法林开始使用的时间下降趋势。
{"title":"Initiation of Anticoagulants During the COVID-19 Pandemic in Sweden: An Interrupted Time Series Analysis","authors":"Per-Jostein Samuelsen,&nbsp;Björn Wettermark,&nbsp;Fredrik Nyberg,&nbsp;Mohammadhossein Hajiebrahimi","doi":"10.1111/bcpt.14119","DOIUrl":"10.1111/bcpt.14119","url":null,"abstract":"<p>The COVID-19 pandemic may have increased anticoagulant initiation due to the thrombogenic nature of the disease or decreased due to the societal impact of the pandemic. We aimed to study the effect of the COVID-19 pandemic on initiation of anticoagulants in Sweden. We conducted a single interrupted time series analysis on the monthly cumulative incidence of nonvitamin K antagonist oral anticoagulants (NOAC), warfarin, or heparins, before and after March 2020, using SCIFI-PEARL dataset. For anticoagulants in total, there were no statistically significant changes or differences in the trends of initiation after the start of the pandemic. There was a slight numerical decrease in initiation after the onset of the pandemic, particularly for NOACs. For individuals aged ≥ 65 years, however, the immediate decrease in initiation was considerable for NOACs. The prepandemic declining trend of warfarin initiation seemed to attenuate, that is, became less negative, after March 2020. We did not find any profound effect of the COVID-19 pandemic on the initiation of anticoagulants in total. However, among individuals aged ≥ 65 years, a notable immediate decrease in initiation of NOACs was observed. Furthermore, the onset of the pandemic may have attenuated the downward temporal trend in initiation of warfarin use.</p>","PeriodicalId":8733,"journal":{"name":"Basic & Clinical Pharmacology & Toxicology","volume":"136 2","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bcpt.14119","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142930551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
List of Reviewers for the January 2025 Issue
IF 2.7 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2025-01-02 DOI: 10.1111/bcpt.14122
{"title":"List of Reviewers for the January 2025 Issue","authors":"","doi":"10.1111/bcpt.14122","DOIUrl":"https://doi.org/10.1111/bcpt.14122","url":null,"abstract":"","PeriodicalId":8733,"journal":{"name":"Basic & Clinical Pharmacology & Toxicology","volume":"136 1","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143110738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
BCPT 2024 Prizes and Awards BCPT 2024获奖情况。
IF 2.7 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-12-26 DOI: 10.1111/bcpt.14123
Jens Lykkesfeldt, Ulf Simonsen
{"title":"BCPT 2024 Prizes and Awards","authors":"Jens Lykkesfeldt,&nbsp;Ulf Simonsen","doi":"10.1111/bcpt.14123","DOIUrl":"10.1111/bcpt.14123","url":null,"abstract":"","PeriodicalId":8733,"journal":{"name":"Basic & Clinical Pharmacology & Toxicology","volume":"136 1","pages":""},"PeriodicalIF":2.7,"publicationDate":"2024-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142891725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Protective Effects of Baicalein and Bergenin Against Gentamicin-Induced Hepatic and Renal Injuries in Rats: An Immunohistochemical and Biochemical Study 黄芩素和卑尔根素对庆大霉素致大鼠肝肾损伤的保护作用:免疫组织化学和生化研究。
IF 2.7 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-12-26 DOI: 10.1111/bcpt.14121
Fazile Nur Ekinci Akdemir, Serkan Yildirim, Fatih Mehmet Kandemir, Sefa Küçükler, Ersen Eraslan, Mustafa Can Güler

Background

Drug-induced organ toxicity is a significant health concern, with gentamicin known for its effective antibacterial properties but also severe side effects, particularly cytotoxicity in liver and kidney tissues. This current study observed the preventive role of baicalein and bergenin against hepatic and renal injuries caused by gentamicin in rats.

Methods

Thirty-two male Sprague Dawley rats were divided into four groups, namely, control, gentamicin (gentamicin 80 mg/kg/day), baicalein (gentamicin 80 mg/kg/day + baicalein 100 mg/kg/day) and bergenin (gentamicin 80 mg/kg/day + bergenin 100 mg/kg/day). Hepatotoxicity and nephrotoxicity were induced by giving gentamicin (80 mg/kg/day). We evaluated the biochemical markers, including alkaline phosphatase (ALP), urea, alanine transaminase (ALT), creatinine and aspartate transaminase (AST) levels, antioxidant enzymes, oxidative stress parameters and histopathological and immunohistochemical changes.

Results

Gentamicin increased oxidative stress parameters and decreased antioxidant activity. The treatment with baicalein and bergenin significantly restored these markers.

Conclusions

Baicalein and bergenin significantly mitigated gentamicin-induced hepatic and renal toxicity by restoring biochemical markers, reducing oxidative stress and enhancing antioxidant enzyme activity. Histopathological and immunohistochemical analyses confirmed the protective effects of both compounds against organ damage. No statistically significant differences were observed between the two drugs for these parameters. These results suggest their potential as therapeutic agents to prevent gentamicin-induced organ toxicity.

背景:药物诱导的器官毒性是一个重要的健康问题,庆大霉素以其有效的抗菌特性而闻名,但也有严重的副作用,特别是对肝脏和肾脏组织的细胞毒性。本研究观察了黄芩素和卑尔根素对庆大霉素致大鼠肝、肾损伤的预防作用。方法:雄性sd大鼠32只,随机分为4组,分别为对照组、庆大霉素组(庆大霉素80 mg/kg/d)、黄芩素组(庆大霉素80 mg/kg/d +黄芩素100 mg/kg/d)和豆根素组(庆大霉素80 mg/kg/d +豆根素100 mg/kg/d)。庆大霉素(80 mg/kg/d)引起肝毒性和肾毒性。我们评估了生化指标,包括碱性磷酸酶(ALP)、尿素、丙氨酸转氨酶(ALT)、肌酐和天冬氨酸转氨酶(AST)水平、抗氧化酶、氧化应激参数以及组织病理学和免疫组织化学变化。结果:庆大霉素增加氧化应激参数,降低抗氧化活性。黄芩素和卑尔根素处理显著恢复了这些标记。结论:黄芩素和卑尔根素可通过恢复生化指标、降低氧化应激和增强抗氧化酶活性,显著减轻庆大霉素引起的肝、肾毒性。组织病理学和免疫组织化学分析证实了这两种化合物对器官损伤的保护作用。两种药物在这些参数上没有统计学上的显著差异。这些结果表明它们有可能作为治疗药物来预防庆大霉素引起的器官毒性。
{"title":"Protective Effects of Baicalein and Bergenin Against Gentamicin-Induced Hepatic and Renal Injuries in Rats: An Immunohistochemical and Biochemical Study","authors":"Fazile Nur Ekinci Akdemir,&nbsp;Serkan Yildirim,&nbsp;Fatih Mehmet Kandemir,&nbsp;Sefa Küçükler,&nbsp;Ersen Eraslan,&nbsp;Mustafa Can Güler","doi":"10.1111/bcpt.14121","DOIUrl":"10.1111/bcpt.14121","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Drug-induced organ toxicity is a significant health concern, with gentamicin known for its effective antibacterial properties but also severe side effects, particularly cytotoxicity in liver and kidney tissues. This current study observed the preventive role of baicalein and bergenin against hepatic and renal injuries caused by gentamicin in rats.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Thirty-two male Sprague Dawley rats were divided into four groups, namely, control, gentamicin (gentamicin 80 mg/kg/day), baicalein (gentamicin 80 mg/kg/day + baicalein 100 mg/kg/day) and bergenin (gentamicin 80 mg/kg/day + bergenin 100 mg/kg/day). Hepatotoxicity and nephrotoxicity were induced by giving gentamicin (80 mg/kg/day). We evaluated the biochemical markers, including alkaline phosphatase (ALP), urea, alanine transaminase (ALT), creatinine and aspartate transaminase (AST) levels, antioxidant enzymes, oxidative stress parameters and histopathological and immunohistochemical changes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Gentamicin increased oxidative stress parameters and decreased antioxidant activity. The treatment with baicalein and bergenin significantly restored these markers.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Baicalein and bergenin significantly mitigated gentamicin-induced hepatic and renal toxicity by restoring biochemical markers, reducing oxidative stress and enhancing antioxidant enzyme activity. Histopathological and immunohistochemical analyses confirmed the protective effects of both compounds against organ damage. No statistically significant differences were observed between the two drugs for these parameters. These results suggest their potential as therapeutic agents to prevent gentamicin-induced organ toxicity.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8733,"journal":{"name":"Basic & Clinical Pharmacology & Toxicology","volume":"136 1","pages":""},"PeriodicalIF":2.7,"publicationDate":"2024-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142891727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Preclinical Evidence for a Drug–Drug Interaction Between Cannabinol and Melatonin 大麻酚和褪黑素之间药物相互作用的临床前证据。
IF 2.7 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-12-25 DOI: 10.1111/bcpt.14120
Lyndsey L. Anderson, Nicole A. Hawkins, Ka Lai Yip, Michael Udoh, Jennifer A. Kearney, Jonathon C. Arnold

The worldwide legalization of medicinal cannabis has led to an increased use of products made by commercial operators. These products often contain minor cannabinoids such as cannabinol (CBN) which are advertised to improve sleep. Products are also available in which CBN is combined with conventional therapies, with a common product containing both CBN and the widely used sleep-aid melatonin. The combination of CBN and melatonin provides potential for a pharmacokinetic drug–drug interaction (DDI) given that cannabinoids are known to inhibit drug-metabolizing enzymes. Indeed, we recently reported that CBN potently inhibited the CYP1A2-mediated metabolism of caffeine. CYP1A2 is the major hepatic enzyme involved in the metabolism of melatonin; thus, in this study, we aimed to examine whether CBN inhibited CYP1A2-mediated metabolism of melatonin in vitro and in vivo. We found CBN potently inhibited CYP1A2-mediated metabolism of melatonin and increased the apparent oral bioavailability of melatonin in mice with a four-fold increase in the plasma melatonin exposure. Our results provide an additional example of a potential DDI involving melatonin.

药用大麻在世界范围内的合法化导致越来越多地使用商业经营者生产的产品。这些产品通常含有少量的大麻素,如大麻酚(CBN),它被宣传为可以改善睡眠。还有一些产品将CBN与传统疗法结合使用,一种常见的产品同时含有CBN和广泛使用的助眠褪黑激素。鉴于大麻素已知可抑制药物代谢酶,CBN和褪黑素的组合为药代动力学药物-药物相互作用(DDI)提供了潜力。事实上,我们最近报道了CBN有效抑制cyp1a2介导的咖啡因代谢。CYP1A2是参与褪黑素代谢的主要肝脏酶;因此,在本研究中,我们旨在研究CBN是否在体外和体内抑制cyp1a2介导的褪黑激素代谢。我们发现CBN能有效地抑制cyp1a2介导的褪黑素代谢,并增加褪黑素的口服生物利用度,使血浆褪黑素暴露增加四倍。我们的结果提供了一个涉及褪黑素的潜在DDI的额外例子。
{"title":"Preclinical Evidence for a Drug–Drug Interaction Between Cannabinol and Melatonin","authors":"Lyndsey L. Anderson,&nbsp;Nicole A. Hawkins,&nbsp;Ka Lai Yip,&nbsp;Michael Udoh,&nbsp;Jennifer A. Kearney,&nbsp;Jonathon C. Arnold","doi":"10.1111/bcpt.14120","DOIUrl":"10.1111/bcpt.14120","url":null,"abstract":"<div>\u0000 \u0000 <p>The worldwide legalization of medicinal cannabis has led to an increased use of products made by commercial operators. These products often contain minor cannabinoids such as cannabinol (CBN) which are advertised to improve sleep. Products are also available in which CBN is combined with conventional therapies, with a common product containing both CBN and the widely used sleep-aid melatonin. The combination of CBN and melatonin provides potential for a pharmacokinetic drug–drug interaction (DDI) given that cannabinoids are known to inhibit drug-metabolizing enzymes. Indeed, we recently reported that CBN potently inhibited the CYP1A2-mediated metabolism of caffeine. CYP1A2 is the major hepatic enzyme involved in the metabolism of melatonin; thus, in this study, we aimed to examine whether CBN inhibited CYP1A2-mediated metabolism of melatonin in vitro and in vivo. We found CBN potently inhibited CYP1A2-mediated metabolism of melatonin and increased the apparent oral bioavailability of melatonin in mice with a four-fold increase in the plasma melatonin exposure. Our results provide an additional example of a potential DDI involving melatonin.</p>\u0000 </div>","PeriodicalId":8733,"journal":{"name":"Basic & Clinical Pharmacology & Toxicology","volume":"136 1","pages":""},"PeriodicalIF":2.7,"publicationDate":"2024-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142891726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Serum Ethanol Concentrations in Relation to Sex and Age in Patients Admitted to a Large Emergency Department During 2015–2020 2015-2020年大型急诊科住院患者血清乙醇浓度与性别和年龄的关系
IF 2.7 4区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-12-25 DOI: 10.1111/bcpt.14118
Aase Bratberg, Ilah Nygaard, Kari Løhne, Ingebjørg Gustavsen, Mimi Stokke Opdal

We examined the number of patients tested for serum ethanol concentration (SEC) at admission to a large Emergency Department (ED) and the relationship of SEC with sex and age. SEC was analysed by enzymatic method. We retrieved SEC in patient samples from the ED during 2015–2020 from the laboratory information system. Altogether, 174 378 patients were admitted, and 7.3% were tested for SEC. Of these, 35.3% had a positive test. The percentage of patients tested increased from 4.8% in 2015 to 14.4% in 2020. A total of 416 patients had more than one positive SEC. For individual data, we included the first positive test per patient, n = 3607. Of these, 73% were men and 27% were women. The median SEC for both men and women was 1.9 g/L. About 4.4% had a SEC ≥ 3.5 g/L. The median SEC in patients aged 30–59 years was 0.2 g/L higher than the 12–29 and ≥ 60 age groups. In conclusion, the increase in the percentage of patients tested did not lead to a corresponding increase in ethanol-positive tests. There was a large predominance of men, the median SEC was the same for men and women and highest in the 30–59 age group.

我们研究了在一家大型急诊科(ED)入院时检测血清乙醇浓度(SEC)的患者数量,以及SEC与性别和年龄的关系。用酶法对SEC进行分析。我们从实验室信息系统中检索2015-2020年间急诊科患者样本中的SEC。总共有174 378名患者入院,7.3%的患者接受了SEC检测,其中35.3%的患者检测呈阳性。接受检测的患者比例从2015年的4.8%增加到2020年的14.4%。共有416例患者有一个以上的SEC阳性。对于个体数据,我们纳入了每个患者的第一个阳性检测,n = 3607。其中73%是男性,27%是女性。男性和女性的中位数SEC均为1.9 g/L。约4.4%的人SEC≥3.5 g/L。30-59岁患者的中位SEC比12-29岁和≥60岁年龄组高0.2 g/L。总之,接受检测的患者百分比的增加并没有导致乙醇阳性检测的相应增加。男性占多数,男性和女性的中位数SEC相同,在30-59岁年龄组中最高。
{"title":"Serum Ethanol Concentrations in Relation to Sex and Age in Patients Admitted to a Large Emergency Department During 2015–2020","authors":"Aase Bratberg,&nbsp;Ilah Nygaard,&nbsp;Kari Løhne,&nbsp;Ingebjørg Gustavsen,&nbsp;Mimi Stokke Opdal","doi":"10.1111/bcpt.14118","DOIUrl":"10.1111/bcpt.14118","url":null,"abstract":"<p>We examined the number of patients tested for serum ethanol concentration (SEC) at admission to a large Emergency Department (ED) and the relationship of SEC with sex and age. SEC was analysed by enzymatic method. We retrieved SEC in patient samples from the ED during 2015–2020 from the laboratory information system. Altogether, 174 378 patients were admitted, and 7.3% were tested for SEC. Of these, 35.3% had a positive test. The percentage of patients tested increased from 4.8% in 2015 to 14.4% in 2020. A total of 416 patients had more than one positive SEC. For individual data, we included the first positive test per patient, <i>n</i> = 3607. Of these, 73% were men and 27% were women. The median SEC for both men and women was 1.9 g/L. About 4.4% had a SEC ≥ 3.5 g/L. The median SEC in patients aged 30–59 years was 0.2 g/L higher than the 12–29 and ≥ 60 age groups. In conclusion, the increase in the percentage of patients tested did not lead to a corresponding increase in ethanol-positive tests. There was a large predominance of men, the median SEC was the same for men and women and highest in the 30–59 age group.</p>","PeriodicalId":8733,"journal":{"name":"Basic & Clinical Pharmacology & Toxicology","volume":"136 1","pages":""},"PeriodicalIF":2.7,"publicationDate":"2024-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11669836/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142891728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Basic & Clinical Pharmacology & Toxicology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1